Distinguishing post-COVID from long-COVID in adults: Development and validation of a biomarker signature using targeted proteomics and machine learning in a cross-sectional observational study
PLOS One · 27.02.2026 · 21 (2) · e0338451
DOI: 10.1371/journal.pone.0338451 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift PLOS One, online erschienen am 27.02.2026. Verfasst von Franziska Meyer und 9 weiteren Autor:innen. Beteiligte Einrichtung: Hochgebirgsklinik Davos, Davos, Switzerland. Hauptthemen laut MEDLINE: COVID-19, Proteomics, Machine Learning. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
COVID-19 can have diverse clinical manifestations, ranging from asymptomatic infection to critical illness with multiorgan involvement. While many patients recover fully, others develop long-COVID, a heterogeneous condition marked by persistent symptoms beyond the acute phase. The immunological pathomechanisms between long-COVID and other post-acute recovery states remain unclear.
Objective
To characterize and compare clinical, pulmonary, and proteomic profiles of patients with long-COVID (LC) and those recovering from severe COVID-19 without long-COVID (post-severe-COVID, PC), and to evaluate the predictive potential of machine learning–based biomarker analysis.
Methods
In this monocentric, prospective observational study with a cross-sectional design, patients undergoing rehabilitation were included at admission. Clinical data, detailed symptom profiles, and lung function testing, including diffusing capacity of the lungs, were collected. Serum proteomics covering immune response and inflammation panels was performed, and a Random Forest classifier was applied to identify biomarkers differentiating LC and PC.
Results
LC (n = 24) patients were younger (52 years vs. 58 years in PC), predominantly female (66.7% vs. 30.0% in PC), and reported fatigue, neurocognitive symptoms, and exercise intolerance, whereas PC (n = 40) patients showed greater pulmonary impairment, as shown by reduced diffusing capacity (46% vs. 72.5% in LC p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Hochgebirgsklinik Davos, Davos, Switzerland.
- Faculty of Medicine, University of Zurich, Zurich, Switzerland.
- Allergy Unit, Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.
- Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany.
- Christine Kühne-Center for Allergy Research and Education, Davos, Switzerland.
- Swiss Institute for Allergy and Asthma Research, Davos, Switzerland.
ORCID-Profile: Stephan Traidl, Felicia Sandberg
Zitieren
APA
Meyer, F., Traidl, S., Ameri, M., Dreher, A., Abu-Rashed-Kufs, N., Vontobel, J., Möhrenschlager, M., Duchna, H. W., Sandberg, F., & Brüggen, M. C. (2026). Distinguishing post-COVID from long-COVID in adults: Development and validation of a biomarker signature using targeted proteomics and machine learning in a cross-sectional observational study. PLOS One, 21(2), e0338451. https://doi.org/10.1371/journal.pone.0338451
Vancouver
Meyer F, Traidl S, Ameri M, Dreher A, Abu-Rashed-Kufs N, Vontobel J, et al. Distinguishing post-COVID from long-COVID in adults: Development and validation of a biomarker signature using targeted proteomics and machine learning in a cross-sectional observational study. PLOS One. 2026;21(2):e0338451. doi:10.1371/journal.pone.0338451
BibTeX
@article{Meyer2026,
author = {Meyer, Franziska and Traidl, Stephan and Ameri, Milad and Dreher, Anita and Abu-Rashed-Kufs, Nevine and Vontobel, Jan and Möhrenschlager, Matthias and Duchna, Hans-Werner and Sandberg, Felicia and Brüggen, Marie-Charlotte},
title = {Distinguishing post-COVID from long-COVID in adults: Development and validation of a biomarker signature using targeted proteomics and machine learning in a cross-sectional observational study},
journal = {PLOS One},
year = {2026},
volume = {21},
number = {2},
pages = {e0338451},
doi = {10.1371/journal.pone.0338451}
}
EUVIMED